Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Quarterly Earnings Results, Beats Estimates By $1.67 EPS

05 May 2026, 21:16 by Amy Steele · The Cerbat Gem

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.67 by $1.67, FiscalAI reports. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm’s quarterly revenue was up 19.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.68 earnings per share.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

Record Q1 results — total revenue of $1.07B (+19% YoY), non-GAAP adjusted EPS of $6.34 and $408M cash from operations, and management reaffirmed full‑year revenue guidance of $4.25–4.5B.
Ziihera (zanidatamab) sBLA accepted under Real‑Time Oncology Review with priority review and a PDUFA date of August 25, 2026; company highlights HERIZON‑GEA‑01 data (triplet median OS 26.4 months) and plans to launch immediately on approval.
Broad commercial momentum — XYWAV $408M (18% growth, ~16,600 active patients), Epidiolex $250M (15% growth, 16% volume growth), Zepzelca $101M (60% growth) and Modeyso $41M with ~500 patients treated and a stated ~$500M peak potential.
Multiple upcoming clinical catalysts that could drive value — mid‑year second interim OS readout for zanidatamab in GEA, ACTION (Modeyso) topline expected late‑2026/early‑2027, and EmpowHER (breast cancer) enrollment on track for top‑line in late‑2027/early‑2028.
Management cautions on second‑half headwinds — anticipated growth of high‑sodium oxybate generics and possible new wake‑promoting entrants (and declining XYREM/authorized generic sales) could pressure the oxybate franchise, and Zepzelca second‑line use is expected to decline.

Jazz Pharmaceuticals Stock Up 2.0%

Jazz Pharmaceuticals stock traded up $4.20 during midday trading on Tuesday, hitting $212.26. 1,214,968 shares of the company were exchanged, compared to its average volume of 920,288. The company’s fifty day moving average price is $190.45 and its 200-day moving average price is $171.65. The company has a market cap of $13.32 billion, a PE ratio of -35.55, a price-to-earnings-growth ratio of 0.36 and a beta of 0.27. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals has a fifty-two week low of $97.50 and a fifty-two week high of $212.57.

Insider Activity

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,287 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the transaction, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at $1,191,305.28. This represents a 16.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the transaction, the senior vice president directly owned 28,728 shares in the company, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 74,015 shares of company stock worth $14,180,486 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd raised its position in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares in the last quarter. Geneos Wealth Management Inc. raised its position in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $53,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $63,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. Wells Fargo & Company lifted their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Leerink Partners lifted their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Needham & Company LLC boosted their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Morgan Stanley boosted their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $216.87.

Check Out Our Latest Research Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.